Return on Equity (ROE)
Higher than 88% of Healthcare sector peers
Updated 188h ago
Sector Performance
88th percentileGSK
40.9%
Sector Median
8.9%
Sector Avg
30.6%
Deep Analysis
GSK plc (GSK) has a Return on Equity (ROE) of 40.9% as of June 2026.
This places GSK in the 88th percentile of the Healthcare sector, which has a median Return on Equity (ROE) of 8.9% and a sector average of 30.6%. GSK's Return on Equity (ROE) is 359.6% above the sector median, a significant divergence that warrants closer examination. In context: ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.
Frequently Asked Questions
What does the Return on Equity (ROE) tell investors about GSK?
ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.
How is the Return on Equity (ROE) calculated?
Return on Equity (ROE) is calculated as: Net Income / Shareholders' Equity.
How does GSK's Return on Equity (ROE) compare to its sector?
GSK's Return on Equity (ROE) of 40.9% compares to a Healthcare sector median of 8.9%, placing it in the 88th percentile.
Who are GSK's closest peers by Return on Equity (ROE)?
The closest Healthcare peers by Return on Equity (ROE) include: ZBH (6.1%), TECH (5.3%), RVTY (3.2%), BIO (2.5%), BEAM (-5.8%).
The Formula
Net Income / Shareholders' Equity
Why It Matters
ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.
Master GSK's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full GSK research report →GSK
40.9%
Sector Median
8.9%
Sector Avg
30.6%
How GSK's Return on Equity (ROE) compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.